Research
Hormonal
GLP-1R agonists improve cardiovascular risk factors by reducing systolic and diastolic blood pressure and total cholesterol concentrations.
Beyond weight loss, these medications also help lower blood pressure and cholesterol, which are key risk factors for heart disease. This makes them particularly useful for patients with metabolic syndrome.
WeakSupportsHIGH confidence
In the overall analysis, GLP-1R agonists had beneficial effects on systolic and diastolic blood pressure, plasma concentrations of cholesterol, and glycaemic control.
Why this rating
Meta-analysis of 25 RCTs.
Source
Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials
Tina Vilsbøll et al. · BMJ · 2012
DOI 10.1136/bmj.d7771
Meta-analysis · 25 studiesCited 953×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Treatment with glucagon-like peptide-1 receptor (GLP-1R) agonists (exenatide or liraglutide) at clinically relevant doses for at least 20 weeks results in significant weight loss in overweight or obese patients, regardless of type 2 diabetes status.Weak
- GLP-1R agonists improve glycaemic control in patients with type 2 diabetes by reducing HbA1c and increasing the proportion of patients achieving target HbA1c levels, without causing significant hypoglycemia.Weak
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →